Conference Correspondent

Lenalidomide/Dexamethasone versus Bortezomib/Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma: Results of the Phase 3 SWOG S0777 Trial

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent — December 4, 2015

Randomized Phase 2 Study of the All-Oral Combination of Ixazomib plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent — December 4, 2015

ELOQUENT-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma—3-Year Safety and Efficacy Follow-Up

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent — December 4, 2015

Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-Up of the HOVON-65/GMMG-HD4 Trial

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent — December 4, 2015

Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (CHAMPION-1)

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent — December 4, 2015

Safety of Pomalidomide/Low-Dose Dexamethasone Treatment in Renally Impaired Patients with Relapsed or Refractory Multiple Myeloma

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent — December 4, 2015

Pomalidomide/Dexamethasone/Ixazomib versus Pomalidomide/Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma: Results of Phase 1/2 Alliance A061202

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent — December 4, 2015

Novel Kinesin Spindle Protein Inhibitor Filanesib Plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent — December 4, 2015

Ibrutinib plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: Results of an Ongoing Phase 1/2b Study (PCYC-1119)

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent — December 4, 2015

Pembrolizumab plus Lenalidomide/Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (KEYNOTE-023)

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent — December 4, 2015

Page 26 of 44

23
24
25
26
27
28
29